The Talc Cases and the Bankruptcy Maneuver Courts Keep Rejecting

The talcum powder litigation against Johnson & Johnson is the biggest active mass tort in the federal court system, more than 67,000 cases pending in a single MDL. But the thing that makes it genuinely unusual isn't its size or even the underlying allegations, which follow a familiar product-liability pattern. It's the years-long, three-times-rejected attempt by one of the world's most valuable companies to make the entire problem disappear through a bankruptcy maneuver, despite not being anywhere close to bankrupt. That strategy, and the courts' repeated refusal to bless it, is the real story of this litigation, and it's a genuinely instructive one.

Here's a neutral rundown: what the cases allege, the bankruptcy gambit and why it keeps failing, and where things actually stand in 2026.

What the lawsuits claim

The allegations center on J&J's talc-based products, most famously Johnson's Baby Powder and Shower to Shower, and two distinct injuries. One set of plaintiffs alleges that long-term use of talcum powder caused ovarian cancer. Another alleges that the talc was contaminated with asbestos, a known carcinogen, and that exposure caused mesothelioma, the cancer most associated with asbestos. The common thread is that the products were marketed as safe for everyday use, including by women applying them for personal hygiene over many years, and that the company knew or should have known of the risks and failed to warn.

J&J has consistently denied that its talc products cause cancer and maintained that they don't contain asbestos, defending the safety of the products throughout. The company eventually transitioned its baby powder to a cornstarch formulation, while continuing to contest the cancer claims in court. As is typical in these cases, the science is contested, and a federal regulatory body, the FDA, maintains information on talc and cosmetic safety reflecting the ongoing scrutiny of the question.

The litigation's structure

The federal cases are consolidated in MDL 2738, in the U.S. District Court for the District of New Jersey, before Judge Michael Shipp. By 2026 it held well over 67,000 pending cases, making it the largest active MDL in the country. As with any multidistrict litigation, these remain individual cases pooled for common pretrial work, not a class action, and they run alongside a substantial body of cases in various state courts, which have produced their own trials and verdicts over the years.

Those verdicts have been a mixed and dramatic bag. Juries have at times returned enormous awards, including, in late 2025, a verdict exceeding a billion dollars for a single mesothelioma plaintiff, one of the largest in the litigation's history, and other large awards before and since. J&J has also won defense verdicts, and some large plaintiff awards have been reduced or overturned on appeal. Separately, the company agreed to pay hundreds of millions of dollars to settle consumer-protection claims brought by dozens of state attorneys general over its marketing, a resolution distinct from the individual injury cases and one that didn't resolve them.

The Texas Two-Step: the maneuver at the center

Now the part that sets this litigation apart. Facing tens of thousands of claims, J&J turned to a controversial legal strategy known as the "Texas Two-Step" bankruptcy, and understanding it explains everything that's happened since.

The maneuver works, in concept, like this. A large, financially healthy company facing mass tort liability uses a state's corporate-restructuring law to split itself, creating a new subsidiary and assigning the talc liabilities to that subsidiary. The subsidiary, now holding the liabilities, then files for bankruptcy. The goal is to channel all the injury claims into the bankruptcy proceeding, where they can be resolved collectively through a court-approved plan, often funded by the healthy parent, while halting the individual lawsuits and the unpredictable jury verdicts that come with them. J&J pursued this through subsidiaries, first one called LTL Management, later one called Red River Talc, proposing settlement funds that grew over successive attempts into the multibillion-dollar range, figures around eight to ten billion dollars to resolve the bulk of the ovarian cancer claims.

The appeal to the company is obvious: bankruptcy can resolve mass liabilities all at once, on terms the company helps shape, while stopping the bleed of individual trials. The objection is equally clear, and it's what courts have seized on.

Why courts keep rejecting it

J&J has attempted this bankruptcy strategy three times. All three have been rejected, and the reasoning is consistent and worth understanding.

The core problem is that bankruptcy is designed for entities that are actually insolvent, financially distressed companies that genuinely cannot pay their debts, and the law's protections exist to fairly distribute a limited pool among creditors. J&J is one of the most valuable companies on earth, nowhere near insolvent. Courts confronting the maneuver have concluded, in essence, that a solvent, financially healthy company doesn't belong in bankruptcy, and that using the bankruptcy system as a litigation-management device, a way to corral and cap mass tort claims, isn't what the Bankruptcy Code is for. A federal bankruptcy judge rejected the most recent attempt on roughly these grounds, finding the subsidiary did not belong in bankruptcy proceedings, and there were also pointed questions about irregularities in how the plan's required creditor votes were obtained.

Critics framed the strategy as an attempt to strip injured plaintiffs of their right to a jury trial and to cap the company's liability below what juries might award, all while the solvent parent shielded itself behind a subsidiary it created for the purpose. After the most recent rejection, J&J announced it would not appeal and would instead return to defending the cases in court. That decision marked a turning point: the bankruptcy off-ramp, after three tries, was closed, and the litigation went back to being a conventional mass tort.

Where things stand in 2026

With the bankruptcy strategy abandoned, the litigation in 2026 looks, for the first time in a while, like an ordinary, if enormous, mass tort moving toward its normal milestones.

The MDL is progressing toward bellwether trials, the representative test cases that, as in any mass tort, will help reveal what the claims are worth in front of juries and drive any eventual resolution. The first federal bellwether has been working toward a trial date. Settlement discussions have continued in the background, with a court-appointed mediator convening sessions under the MDL judge's order, though J&J has publicly maintained that it does not currently intend to offer a global settlement, signaling it intends to litigate rather than write one large check. Meanwhile, individual trials in state courts continue to produce verdicts, keeping pressure on the company and continuing to generate the data points that shape settlement leverage.

There's also been movement on the science front, with new research touching the talc-ovarian cancer question, the kind of development that can influence how juries and courts weigh the claims, though as always a single study doesn't decide the litigation.

So the honest snapshot for 2026: the largest active MDL in the country, the bankruptcy escape route closed after three failed attempts, bellwether trials approaching, no global injury settlement in place, and a steady stream of individual state-court verdicts continuing. After years as what one observer called a "bankruptcy sideshow," the talc litigation is functioning as a real mass tort again.

The broader lesson

The talc saga is worth following even for people with no connection to it, because it tested something larger than these particular claims: whether a solvent company can use bankruptcy to manage mass tort liability on its own terms. The courts' repeated answer, no, this isn't what bankruptcy is for, has implications well beyond J&J, and it's drawn attention from lawmakers, some of whom have floated legislation to restrict profitable companies from using subsidiary bankruptcies to limit mass tort exposure. The maneuver isn't unique to this case, and how courts handled it here shapes whether other corporations try it.

A practical note for anyone tracking the litigation, offered as fact rather than advice: statutes of limitations in talc cases vary by state and turn on when a person reasonably connected their diagnosis to the product, and given the long latency between use and a cancer diagnosis, that timing question is genuinely individual. As for the cases themselves, the path forward now runs through the ordinary mass-tort machinery, bellwethers, then either a negotiated resolution or continued individual trials, the same arc described in how mass tort settlements pay out. We'll update this as the bellwether trials actually run and as any settlement posture shifts, because after the bankruptcy detour, those are once again the developments that will move it.